NO20070927L - Anti-rhesus D rekombinant polyklonalt antistoff og fremgangsmater for fremstilling. - Google Patents
Anti-rhesus D rekombinant polyklonalt antistoff og fremgangsmater for fremstilling.Info
- Publication number
- NO20070927L NO20070927L NO20070927A NO20070927A NO20070927L NO 20070927 L NO20070927 L NO 20070927L NO 20070927 A NO20070927 A NO 20070927A NO 20070927 A NO20070927 A NO 20070927A NO 20070927 L NO20070927 L NO 20070927L
- Authority
- NO
- Norway
- Prior art keywords
- rhd
- cells
- polyclonal antibody
- recombinant polyclonal
- library
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
Sammendrag Oppfinnelsen relateres til en fremgangsmåte for fremstilling av anti-RhD rekombinant polyklonal antistoffkomposisjon (anti-RhD rpAb). Fremgangmåten består i å erverve en kolleksjon av celler transfektert med et bibliotek av anti-RhD antistoff ekspresjonsvektorer, hvori hver celle i kolleksjonen er i stand til å uttrykke fra et nukleinsyresegment som består av en VH og VL, et medlem av biblioteket, som koder for et bestemt medlem av anti-RhD rekombinant polyklonal antistoffkomposisjon og som ligger i det samme setet i genomet til individuelle celler i ovennevnte kolleksjon. Cellene blir dyrket under egnede forhold for ekspresjon av det rekombinante polyklonale antistoffet, som blir ervervet fra cellene eller kultursupernatanten. Nukleinsyresegmentene som koder for anti-RhD rpAb blir introdusert inn i cellene ved transfeksjon med et bibliotek av vektorer for sete-spesifikk integrasjon. Den foreliggende fremgangsmåten er egnet for å fremstille anti-RhD rpAb, og gjør det derved tilgjengelig med en førsteklasses erstatning av plasma-derivert profylaktiske og terapeutiske immunoglobulinprodukter.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200401133 | 2004-07-20 | ||
DKPA200401992 | 2004-12-22 | ||
PCT/DK2005/000501 WO2006007850A1 (en) | 2004-07-20 | 2005-07-18 | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070927L true NO20070927L (no) | 2007-04-19 |
Family
ID=35159789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070927A NO20070927L (no) | 2004-07-20 | 2007-02-19 | Anti-rhesus D rekombinant polyklonalt antistoff og fremgangsmater for fremstilling. |
Country Status (13)
Country | Link |
---|---|
US (2) | US8198415B2 (no) |
EP (2) | EP1771483A1 (no) |
JP (1) | JP4926054B2 (no) |
KR (1) | KR20070038556A (no) |
AU (1) | AU2005263331B8 (no) |
BR (1) | BRPI0513706A (no) |
CA (1) | CA2574062A1 (no) |
EA (1) | EA014182B1 (no) |
IL (1) | IL179658A (no) |
MX (1) | MX2007000644A (no) |
NO (1) | NO20070927L (no) |
NZ (1) | NZ552265A (no) |
WO (1) | WO2006007850A1 (no) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
PT1583830E (pt) * | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
KR101319848B1 (ko) | 2004-07-20 | 2013-10-18 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법 |
US7850965B2 (en) | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
TW200846362A (en) * | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
ES2582386T3 (es) | 2007-03-01 | 2016-09-12 | Symphogen A/S | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico |
NZ578851A (en) * | 2007-03-01 | 2011-09-30 | Symphogen As | Method for cloning cognate antibodies |
EP2134747A2 (en) * | 2007-03-06 | 2009-12-23 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
JP5941616B2 (ja) * | 2007-05-25 | 2016-06-29 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組み換えポリクローナルタンパク質を製造する方法 |
WO2009030237A2 (en) * | 2007-09-07 | 2009-03-12 | Symphogen A/S | Methods for recombinant manufacturing of anti-rsv antibodies |
EP2045602A1 (en) | 2007-10-04 | 2009-04-08 | Symphogen A/S | Potency assay |
US20090186423A1 (en) * | 2007-11-22 | 2009-07-23 | Symphogen A/S | Method for Characterization of a Recombinant Polyclonal Protein |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
EP4238993A3 (en) * | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
JP2011518790A (ja) * | 2008-04-23 | 2011-06-30 | シムフォゲン・アクティーゼルスカブ | ポリクローナルタンパク質を製造する方法 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2328926A1 (en) * | 2008-08-26 | 2011-06-08 | Symphogen A/S | Treatment of thrombocytopenia |
BRPI0917352A2 (pt) * | 2008-08-29 | 2017-08-22 | Symphogen As | Métodos para produção de uma biblioteca de pares cognatos que compreende sequências ligadas que codificam regiões variáveis e para gerar um vetor que codifica um anticorpo quimérico com regiões de seres humanos constantes e regiões variáveis não humanas, biblioteca de vetores, e método para produção de uma biblioteca de sequências de imunoglobulina derivadas de aves |
CN102137874B (zh) | 2008-08-29 | 2015-02-18 | 西福根有限公司 | 抗表皮生长因子受体的重组抗体组合物 |
CN102265152A (zh) * | 2008-10-06 | 2011-11-30 | 西福根有限公司 | 鉴定和选择用于组合药品的药物候选物 |
FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
AU2010305150A1 (en) | 2009-10-09 | 2012-04-05 | Symphogen A/S | Multiplex quantitation of individual recombinant proteins in a mixture by signature peptides and mass spectrometry |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
WO2013189544A1 (en) * | 2012-06-21 | 2013-12-27 | Synthon B.V. | Method of purifying an antibody |
EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
JP2017528449A (ja) | 2014-08-26 | 2017-09-28 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | アミロイドーシスのための標的化免疫療法 |
WO2017184973A1 (en) | 2016-04-22 | 2017-10-26 | University Of Tennessee Research Foundation | Identifying amyloidogenic proteins & amyloidogenic risk |
SI3631454T1 (sl) | 2017-05-30 | 2023-12-29 | Bristol-Myers Squibb Company | Zdravljenje lag-3 pozitivnih tumorjev |
BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
SG11202012713RA (en) * | 2018-06-22 | 2021-01-28 | Genmab As | Method for producing a controlled mixture of two or more different antibodies |
CN112912392A (zh) | 2018-10-26 | 2021-06-04 | 豪夫迈·罗氏有限公司 | 利用重组酶介导的盒式交换的多特异性抗体筛选方法 |
WO2020205775A1 (en) * | 2019-03-29 | 2020-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Antibodies against programmed cell death protein 1 (pd1) and uses thereof |
EP3947437A1 (en) | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
MX2021015648A (es) | 2019-06-19 | 2022-02-03 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida. |
AU2020296247A1 (en) | 2019-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
BR112021025425A2 (pt) | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre |
CA3140323A1 (en) | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
BR112021025462A2 (pt) | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição |
WO2022150654A2 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
RU2770654C1 (ru) * | 2021-06-17 | 2022-04-20 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) | Способ профилактики тяжелой формы гемолитической болезни новорожденных при резус-иммунизации у беременных с соматической патологией и потерями плода в анамнезе |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985002413A1 (en) | 1983-11-28 | 1985-06-06 | The Board Of Trustees Of The Leland Stanford Jr. U | HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES |
US5126130A (en) * | 1986-11-24 | 1992-06-30 | The Childrens Hospital Incorporated | Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a |
GB8722020D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
GB8722019D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
GB8722018D0 (en) | 1987-09-18 | 1987-10-28 | Central Blood Lab Authority | Human anti-rh(d)monoclonal antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
GB8906129D0 (en) | 1989-03-17 | 1989-05-04 | Central Blood Lab Authority | Pharmaceutical preparations |
GB8919761D0 (en) | 1989-09-01 | 1989-10-18 | Central Blood Lab Authority | Chemical compounds |
WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
BR9305557A (pt) | 1992-06-26 | 1997-03-25 | Aetsrn | Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém |
KR100306635B1 (ko) | 1992-10-21 | 2001-11-30 | 스테판밀테니 | 분비생성물에의한직접적인세포선별 |
US5538848A (en) * | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
PT1231268E (pt) * | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
FR2724182B1 (fr) * | 1994-09-02 | 1996-12-13 | Pasteur Institut | Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
ES2224255T3 (es) * | 1996-06-24 | 2005-03-01 | Zlb Behring Ag | Polipeptidos capaces de formar estructuras de union a antigenos con especificidad por los antigenos de rhesus d, el dna que los codifica y el proceso para su preparacion y uso. |
US6255455B1 (en) * | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US5876925A (en) * | 1996-10-11 | 1999-03-02 | The Trustees Of The University Of Pennsylvania | Magnetically activated cell sorting for production of proteins |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
EP1034262B1 (en) | 1997-11-18 | 2005-08-17 | Pioneer Hi-Bred International, Inc. | Compositions and methods for genetic modification of plants |
CA2333852C (en) | 1998-07-21 | 2007-05-29 | Cobra Therapeutics Limited | A polynucleotide comprising a ubiquitous chromatin opening element (ucoe) |
US20020155114A1 (en) * | 1998-08-31 | 2002-10-24 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
ATE463569T1 (de) | 1999-07-23 | 2010-04-15 | Univ California | Dna-rekombination in eukaryotischen zellen mittels des rekombinationszentrums vom bakteriophag phic31 |
EP1106625A1 (en) | 1999-11-17 | 2001-06-13 | ZLB Bioplasma AG | Rhesus D specific peptide sequences |
CA2400460C (en) | 2000-02-08 | 2009-01-06 | The Regents Of The University Of Michigan | Mapping of differential display of proteins |
EP1385869A2 (en) | 2000-02-08 | 2004-02-04 | The Regents Of The University Of Michigan | Protein mapping |
EP1358202A2 (en) | 2000-02-08 | 2003-11-05 | The Regents Of The University Of Michigan | Protein separation and display |
ATE359819T1 (de) | 2000-05-26 | 2007-05-15 | Symphogen As | Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien |
EP1309709A2 (en) | 2000-07-21 | 2003-05-14 | The United States of America, represented by The Secretary of Agriculture | Methods for the replacement, translocation and stacking of dna in eukaryotic genomes |
US6610472B1 (en) | 2000-10-31 | 2003-08-26 | Genetastix Corporation | Assembly and screening of highly complex and fully human antibody repertoire in yeast |
JP2004514444A (ja) | 2000-11-28 | 2004-05-20 | アプライド モレキュラー エボリューション, インコーポレイテッド | 二重lox組換えに基づく真核生物発現ライブラリーおよび使用方法 |
DE60119580T2 (de) | 2000-12-26 | 2007-04-26 | The Institute For Systems Biology, Seattle | Schnelle und quantitative proteomanalyse und damit zusammenhängende verfahren |
WO2003102539A2 (en) | 2002-05-31 | 2003-12-11 | The Regents Of The University Of Michigan | Automated protein analysis system comprising capillary electrophoresis-tandem mass spectrometry |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
AU2003284227A1 (en) | 2002-10-15 | 2004-05-04 | The Regents Of The University Of Michigan | Multidimensional protein separation system |
US20060275766A1 (en) * | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
KR101319848B1 (ko) | 2004-07-20 | 2013-10-18 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법 |
-
2005
- 2005-07-18 AU AU2005263331A patent/AU2005263331B8/en not_active Ceased
- 2005-07-18 CA CA002574062A patent/CA2574062A1/en not_active Abandoned
- 2005-07-18 EP EP05760588A patent/EP1771483A1/en not_active Withdrawn
- 2005-07-18 MX MX2007000644A patent/MX2007000644A/es active IP Right Grant
- 2005-07-18 BR BRPI0513706-3A patent/BRPI0513706A/pt not_active IP Right Cessation
- 2005-07-18 NZ NZ552265A patent/NZ552265A/en not_active IP Right Cessation
- 2005-07-18 US US11/632,937 patent/US8198415B2/en not_active Expired - Fee Related
- 2005-07-18 KR KR1020077003955A patent/KR20070038556A/ko not_active Application Discontinuation
- 2005-07-18 WO PCT/DK2005/000501 patent/WO2006007850A1/en active Application Filing
- 2005-07-18 EA EA200700249A patent/EA014182B1/ru not_active IP Right Cessation
- 2005-07-18 EP EP08157871A patent/EP1967529A1/en not_active Withdrawn
- 2005-07-18 JP JP2007521793A patent/JP4926054B2/ja not_active Expired - Fee Related
-
2006
- 2006-11-28 IL IL179658A patent/IL179658A/en not_active IP Right Cessation
-
2007
- 2007-02-19 NO NO20070927A patent/NO20070927L/no not_active Application Discontinuation
-
2012
- 2012-06-11 US US13/493,623 patent/US20120322690A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1967529A1 (en) | 2008-09-10 |
MX2007000644A (es) | 2007-03-28 |
EA200700249A1 (ru) | 2007-06-29 |
US20120322690A1 (en) | 2012-12-20 |
KR20070038556A (ko) | 2007-04-10 |
EP1771483A1 (en) | 2007-04-11 |
BRPI0513706A (pt) | 2008-05-13 |
EA014182B1 (ru) | 2010-10-29 |
AU2005263331A1 (en) | 2006-01-26 |
AU2005263331B8 (en) | 2011-06-16 |
IL179658A0 (en) | 2007-05-15 |
AU2005263331B2 (en) | 2011-05-26 |
JP4926054B2 (ja) | 2012-05-09 |
US8198415B2 (en) | 2012-06-12 |
AU2005263331A8 (en) | 2011-06-16 |
WO2006007850A1 (en) | 2006-01-26 |
IL179658A (en) | 2011-08-31 |
US20090017017A1 (en) | 2009-01-15 |
CA2574062A1 (en) | 2006-01-26 |
JP2008509658A (ja) | 2008-04-03 |
NZ552265A (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070927L (no) | Anti-rhesus D rekombinant polyklonalt antistoff og fremgangsmater for fremstilling. | |
Kaplan | Membrane cation transport and the control of proliferation of mammalian cells | |
NO20091235L (no) | Antagonistiske humane lysspesifikke monoklonale antistoffer | |
NO20082716L (no) | Sammensetninger og fremgangsmater for fremstilling av en sammensetning | |
DK1583830T3 (da) | Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner | |
IL201395A (en) | Multi-clonal cell lines and methods for generating multi-clonal cell lines | |
PH12017501025A1 (en) | Antigen binding proteins capable of binding thymic stromal lymphopoietin | |
RU2625033C2 (ru) | Система индикации на основе полноразмерного антитела для эукариотических клеток и ее применение | |
NO20091387L (no) | Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse | |
EA026129B1 (ru) | АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ | |
ES2230908T3 (es) | Procedimiento para la preparacion de celulas recombinantes. | |
WO2007065433A3 (en) | Anti-orthopoxvirus recombinant polyclonal antibody | |
JPH0335800A (ja) | ヘテロ二重特異性モノクローナル抗体の製造法 | |
UA74130C2 (uk) | ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ БІЛКА, СПОРІДНЕНОГО З ПАРАТИРЕОЇДНИМ ГОРМОНОМ (PTHrP), АБО ЙОГО ФУНКЦІОНАЛЬНО АКТИВНОГО ФРАГМЕНТА І/АБО ЙОГО МОДИФІКОВАНОГО ФРАГМЕНТА ДЛЯ ВИРОБНИЦТВА ЛІКАРСЬКОГО ЗАСОБУ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ КАХЕКСІЇ | |
ES2172149T3 (es) | Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos. | |
WO2009030237A3 (en) | Methods for recombinant manufacturing of anti-rsv antibodies | |
JP2010531878A5 (no) | ||
EA022990B1 (ru) | Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок | |
CN106117354A (zh) | 一种全人源抗CD47的全分子IgG抗体及其应用 | |
RU2013152816A (ru) | АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА | |
ATE523523T1 (de) | Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung | |
CN105524176A (zh) | 双特异性融合蛋白 | |
RU2014129729A (ru) | Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов | |
US8394931B2 (en) | Anti-HMGA1 monoclonal antibodies, process for their preparation and their use for the quantitative determination of HMGA1 | |
CN105925578A (zh) | 靶向沉默Neogenin的shRNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |